Moderna (MRNA) Will Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
Moderna (MRNA) Reports Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update
December 10, 2021 7:00 AM ESTModerna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first positive interim data from the Phase 1 study of the Companys quadrivalent seasonal flu vaccine candidate, mRNA-1010. In the study, mRNA-1010 successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers... More
CDC Expands Booster Recommendations To 16-and-17-year-olds - Bloomberg
December 9, 2021 2:30 PM ESTCDC Expands Booster Recommendations To 16-and-17-year-olds - Bloomberg
... MoreBioNTech (BNTX) and Pfizer (PFE) Beneficiaries From Lower Omicron Vaccine Efficacy - SVB Leerink
December 9, 2021 6:28 AM ESTSVB Leerink analyst Daina Graybosch reiterated Market Perform ratings on BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) after the companies confirmed that the protection conferred by vaccination with Comirnaty is 20-fold lower against Omicron compared to wild type... More
Moderna (MRNA) on Watch as Pfizer/BioNTech SE Three Dose Regimen Neutralizes Omicron
December 8, 2021 7:04 AM ESTModerna (NASDAQ: MRNA) shares are on watch as rivals Pfizer/BioNTech SE said three of their vaccine doses neutralize the Omicron variant. Both use similar mRNA technology, so it could be assumed that Moderna's jab has the same impact. Shares of MRNA are down 2% in pre-open trading.
... MoreModerna (MRNA), BioNTech (BNTX) Trade to High as Study Show Reduced Protection of Current Vaccine vs Omicron
December 7, 2021 3:30 PM ESTModerna (NASDAQ: MRNA), BioNTech SE (NASDAQ: BNTX) Trade to High as Study Show Reduced Protection of Current Vaccine vs Omicron
U.S. boosters surge to all-time high on Omicron fears
December 7, 2021 1:37 PM ESTBy Ahmed Aboulenein and Michael Erman
WASHINGTON (Reuters) - Americans are lining up for booster doses of COVID-19 vaccines at a record pace, with concerns about the newly-detected Omicron coronavirus variant spurring millions to get shots, the U.S. government said on Tuesday.
Just under a million people a day received booster doses of one of the three authorized vaccines last week, the highest rate since U.S. regulators gave the nod to additional shots for some adults in September, government data shows.
"In the last week, we've gotten nearly 7 million people a booster; that's a... More
